Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham B15 2TH, United Kingdom.
J Am Coll Cardiol. 2010 Jul 27;56(5):352-61. doi: 10.1016/j.jacc.2010.02.055.
Demand for donor hearts exceeds supply, and a significant number of patients die while awaiting transplantation. Within the pool of currently unused potential donor hearts, a proportion may be suitable for transplantation but are declined due to anticipated poor function. Despite current assessment methods, in some donor hearts accepted for transplantation early graft failure develops in the recipient. Current methods of assessment are inadequate, and there is a potential for biomarkers to improve identification of satisfactory hearts for transplantation or hearts destined to fail in the recipient. Biomarkers are routinely used to diagnose and risk-stratify myocardial infarction, acute coronary syndromes, and heart failure. Some of these might facilitate donor heart assessment. Cardiac troponins, cytokines, inflammatory markers, natriuretic peptides, and intracellular proteins may each have discriminant value. This review details the current status of biomarkers in the assessment of donor hearts.
供体心脏的需求超过了供应，大量患者在等待移植时死亡。在目前未使用的潜在供体心脏中，一部分可能适合移植，但由于预期功能不佳而被拒绝。尽管有目前的评估方法，但在一些接受移植的供体心脏中，受体早期发生移植物衰竭。目前的评估方法不够充分，生物标志物有可能改善对可接受的移植心脏或注定在受体中失败的心脏的识别。生物标志物通常用于诊断和风险分层心肌梗死、急性冠状动脉综合征和心力衰竭。其中一些可能有助于供体心脏的评估。肌钙蛋白、细胞因子、炎症标志物、利钠肽和细胞内蛋白可能都具有鉴别价值。这篇综述详细介绍了生物标志物在供体心脏评估中的现状。
